全球首家!博瑞醫藥(688166.SH)恩替卡韋片通過WHO的PQ認證
格隆匯3月23日丨博瑞醫藥(688166.SH)公佈,近日,公司的恩替卡韋片通過了世界衞生組織(WHO)的PQ(預認證)審核。
恩替卡韋可選擇性抑制乙肝病毒,主要用於治療伴有病毒複製活躍、血清轉氨酶持續增高的慢性乙型肝炎感染。
恩替卡韋是目前WHO和各國臨牀指南推薦的慢性乙型肝炎患者抗病毒醫治的一線用藥,在已經上市核苷類抗乙肝病毒藥物中,恩替卡韋抑制病毒複製的活性最強,具有口服吸收率高、耐藥率低等優點。
博瑞醫藥是全球首家恩替卡韋片通過WHO的PQ認證的企業。據統計,恩替卡韋片2020年全球銷售額為9.008億美元、2021年全球銷售額為7.858億美元(數據來源於Cortellis數據庫)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.